Pharmaceutical

Oncternal stock crashes by 60% as it lays off staff and scraps trials

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.

Sep 14, 2024 - 04:00
Oncternal stock crashes by 60% as it lays off staff and scraps trials
Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.
Read the original article

Tags:

Previous Article

Japan approves updated Covid-19 vaccine to tackle JN.1 variant

Next Article

Cidara axes 30% of staff to focus on flu prevention drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Coherus allies with Mark Cuban to challenge AbbVie for Humira biosimilar

Coherus allies with Mark Cuban to challenge AbbVie for ...

Jun 3, 2023

SGNB-7H4V by Pfizer for Peritoneal Cancer: Likelihood of Approval

SGNB-7H4V by Pfizer for Peritoneal Cancer: Likelihood o...

Jun 20, 2024

Avadel wins FDA approval for narcolepsy drug Lumryz in children

Avadel wins FDA approval for narcolepsy drug Lumryz in ...

Oct 20, 2024